Ibuprofen delayed release - Orbis Biosciences
Alternative Names: ORB 108; ORB-113Latest Information Update: 28 Jul 2022
At a glance
- Originator Orbis Biosciences
- Class Amines; Analgesics; Antipyretics; Antirheumatics; Nonsteroidal anti-inflammatories; Phenylpropionates; Small molecules
- Mechanism of Action Cyclooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Pain
Most Recent Events
- 28 Jul 2022 No recent reports of development identified for preclinical development in Pain in USA (PO, Controlled release)
- 04 May 2020 Orbis Biosciences has been acquired by Adare Pharmaceuticals
- 29 May 2019 Orbis Biosciences has patents and corresponding applications covering sustained release particle formulations, in USA, Canada, Europe, as well as a worldwide application